July 24 (Reuters) - Infinity Pharmaceuticals Inc
:
* INFINITY PHARMACEUTICALS ANNOUNCES TERMINATION OF MERGER AGREEMENT WITH MEI PHARMA
* INFINITY PHARMACEUTICALS INC- EGANELISIB REMAINS PRIMARY VALUE DRIVER FOR INFINITY
* INFINITY PHARMACEUTICALS INC - INFINITY TO EXPLORE STRATEGIC ALTERNATIVES TO MAXIMIZE VALUE FOR STOCKHOLDERS
* INFINITY PHARMACEUTICALS INC - INFINITY TO EXPLORE STRATEGIC ALTERNATIVES TO MAXIMIZE VALUE FOR STOCKHOLDERS
* INFINITY PHARMACEUTICALS INC- INFINITY TO EXPLORE STRATEGIC ALTERNATIVES TO MAXIMIZE VALUE FOR STOCKHOLDERS
* INFINITY PHARMACEUTICALS - COMPANY'S BOARD AND MANAGEMENT TEAM EXPECT TO UNDERTAKE A SERIES OF COST SAVING MEASURES
* INFINITY PHARMACEUTICALS INC- AS A RESULT OF TERMINATION OF MERGER AGREEMENT, INFINITY ENTITLED TO REIMBURSEMENT OF OF $1 MILLION FROM MEI
* INFINITY PHARMACEUTICALS INC - INFINITY HAS POTENTIAL TO RECEIVE AN ADDITIONAL $4 MILLION TERMINATION FEE FROM MEI UNDER CERTAIN CIRCUMSTANCES
* INFINITY PHARMACEUTICALS INC- COMPANY'S BOARD AND MANAGEMENT TEAM EXPECT TO UNDERTAKE A SERIES OF COST SAVING MEASURES
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.